Trial aims to control rare blood cancer without chemotherapy
Disease control
Ongoing
This study is testing a new combination of three drugs (bortezomib, rituximab, and ibrutinib) for people newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this 'chemotherapy-free' approach can effectively control the disease while po…
Phase: PHASE2 • Sponsor: Christian Buske • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC